Celgene Stock Price - CELG

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
North American Extreme
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Celgene Corporation CELG NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  1.93 1.87% 105.33 107.41 104.95 106.23 103.40 12:27:49
Bid Price Ask Price Spread Spread % News
105.31 105.32 0.01 0.01% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
26,984 2,871,872 $ 106.02 $ 304,468,087 3,565,119 58.59 - 107.41
Last Trade Time Type Quantity Stock Price Currency
12:27:49 1 $ 105.32 USD

Celgene Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 74.65B 708.74M $ 4.05B 5.52 13.40 704.90M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 37.00 0.50%

more financials information »

Celgene News

Latest CELG Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CELG Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week100.50107.41100.40102.163,503,2844.834.81%
1 Month99.80107.4197.3099.863,531,0695.535.54%
3 Months92.82107.4191.5597.413,301,44612.5113.48%
6 Months93.42107.4189.0395.603,783,88911.9112.75%
1 Year82.76107.4158.5986.536,693,79022.5727.27%
3 Years99.65147.1758.5997.525,763,1575.685.7%
5 Years94.93147.1758.59102.545,305,14910.4010.96%

Celgene Description

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Recent acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191022 17:42:53